FDA approves Enbrel to treat psoriasis

THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., April 30, 2004 Amgen (N), today announced that Enbrel® (etanercept) has been approved by the U.S. Food and Drug Ad ASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYEministration (FDA) for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The psoriasis indication marks the fifth disease for which ENBREL has received an FDA approval in just over five years.

Psoriasis is a chronic immune disorder in which certain immune cells become overactive and release proteins called cytokines. Tumor necrosis faction (TNF) is one of those cytokines that helps regulate the body's immune response to infection and inflammation. In patients with psoriasis, TNF causes inflammation, which can lead to the formation of painful, often disfiguring psoriasis plaques. As an anti-TNF therapy, ENBREL binds to the over-produced TNF and renders it biologically inactive, which can result in a significant reduction in inflammation.

"Both physicians and patients have expressed a desire for new options to treat psoriasis. ENBREL rapidly cleared psoriasis in many patients and was generally well tolerated in two large clinical trials," said Laura Hamill, vice president and general manager of Amgen's Inflammation Business Unit. "This approval in psoriasis, coupled with our previous indication in psoriatic arthritis, reinforces our commitment to dermatology and our core aspiration of providing treatments that can dramatically improve people's lives."

The approval was based on data from two Phase 3 studies totaling more than 1,200 adults with plaque psoriasis who were treated with ENBREL for up to 12 months. ENBREL was approved with a step-down dosing regimen of 50 mg administered twice-weekly for three months, followed by a maintenance dose of 50 mg weekly thereafter. ENBREL demonstrated rapid and


Page: 1 2 3 4 5

Related medicine news :

1. FDA approves Pfizers Lyrica for the treatment of the two most common forms of neuropathic pain
2. FDA approves Enablex for treatment of overactive bladder
3. FDA approves Fosrenol(R) in end-stage renal disease (ESRD) patients
4. FDA approves Adderall XR (R) to treat ADHD in adults
5. FDA approves EPZICOM
6. FDA approves new labelling for Seroquel in bioplar mania
7. FDA approves Climara Pro to treat menopause symptoms
8. FDA approves new approach to schizophrenia treatment
9. FDA approves new HIV protease inhibitor, Lexiva (TM)
10. FDA approves Wellbutrin XL(TM)
11. FDA approves Baxters ADVATE for the treatment of hemophilia A

Post Your Comments:

(Date:8/28/2020)... ... August 28, 2020 , ... ... set out to continue helping the specialty-diet community connect with great, gluten-free ... products, get coupons, enter giveaways, chat with brands & watch over 50 educational ...
(Date:8/28/2020)... ... August 28, 2020 , ... Ziegler, a ... on its investment in Synchronous Health, a tech-enabled behavioral health and well-being solutions ... of human empathy with artificial intelligence (AI) to increase access and quality of ...
(Date:8/27/2020)... (PRWEB) , ... August 27, 2020 , ... ... has joined the Walk-in Dermatology team in its Greenvale, New York location. ... Nail and Skin Care Institute. She is certified in chemical peels, microdermabrasion, Hydrafacial ...
(Date:8/27/2020)... ... August 27, 2020 , ... Evolution Labs announced today ... their students with Suite360:Mental Health and Prevention, a program developed to help students ... Trafficking Prevention. , Florida schools and districts must provide their students with preventative ...
(Date:8/26/2020)... ... August 26, 2020 , ... Harmony Healthcare IT, ... Best in KLAS Software & Services Report as the Category Leader in Data ... wide variety of complex clinical and financial software systems for enterprise-wide inpatient organizations ...
Breaking Medicine News(10 mins):
(Date:9/3/2020)... ... 2020 , ... Using Analysis of Variance — A Practical Approach:, Perform Statistical ... p.m. EDT, https://www.fdanews.com/anova , How much would it help one’s Quality Management ... one in 90 minutes, one can master a powerful statistical technique in that time ...
(Date:9/2/2020)... ... September 02, 2020 , ... ... Advanced Penetration Technology, LLC, (APT) a Texas- and Indiana-based company ( http://www.aptt3x.com ... The Counter (OTC) products, was today provided results of an independent laboratory ...
(Date:9/1/2020)... ... September 01, 2020 , ... Mara C. ... Laser Surgery at the University of Rochester Medical Center, in Upstate New York. ... in Boston, with clinical faculty from the Harvard and Yale Departments of Dermatology ...
Breaking Medicine Technology:
Cached News: